Artivion (NYSE:AORT – Get Free Report) and Edwards Lifesciences (NYSE:EW – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of current ratings and target prices for Artivion and Edwards Lifesciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artivion | 1 | 0 | 6 | 0 | 2.71 |
| Edwards Lifesciences | 0 | 3 | 23 | 0 | 2.88 |
Artivion currently has a consensus price target of $39.00, suggesting a potential upside of 112.24%. Edwards Lifesciences has a consensus price target of $109.88, suggesting a potential upside of 2.48%. Given Artivion’s higher probable upside, research analysts clearly believe Artivion is more favorable than Edwards Lifesciences.
Institutional & Insider Ownership
86.4% of Artivion shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Artivion has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Profitability
This table compares Artivion and Edwards Lifesciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artivion | -3.65% | 5.12% | 2.36% |
| Edwards Lifesciences | 15.30% | 16.06% | 12.36% |
Valuation & Earnings
This table compares Artivion and Edwards Lifesciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artivion | $441.33 million | 2.03 | $9.77 million | ($0.36) | -51.04 |
| Edwards Lifesciences | $6.67 billion | 9.24 | $1.07 billion | $1.77 | 60.58 |
Edwards Lifesciences has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Summary
Edwards Lifesciences beats Artivion on 10 of the 14 factors compared between the two stocks.
About Artivion
Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
